亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Sepsis Treatment Inactivates Endotoxins Using Molecules Derived From Chitosan Derivative

總結
Purdue University researchers have developed a novel treatment for septicemia involving molecules derived from chitosan. Chitosan is a linear carbohydrate with many commercial and biomedical uses. This treatment inactivates endotoxins, which are toxins associated with certain types of bacteria and stimulates cytokine release (part of the body's inflammatory response that causes swelling and high fever). This new chitosan shows many advantages over current IV treatments for septicemia. This technology can be used to filter endotoxins out of plasmid DNA samples and filter bacteria from water, making contaminated water samples safe to drink.
技術優勢
Stronger affinity for inactivating endotoxinsExcellent biocompatibility upon injection Lower potential to cause hemolysis, complement activation, and inflammatory responsesCan filter endotoxins out of plasmid DNA samples and remove bacteria from water
技術應用
Medical/HealthSepsis treatmentContaminant removal from drinking water
詳細技術說明
Yoon YeoYeo LabPurdue Industrial and Physical Pharmacy
*Abstract

*Background
Septicemia refers to the presence of pathogens in the bloodstream that leads to sepsis, a potentially life-threatening medical condition characterized by whole-body inflammation and the presence of infection. When microbes infect the blood, skin, lungs or other tissues, the body's immune system generates an inflammatory response in an attempt to fight the infection. The body's immune response to the infection causes the characteristic symptoms of sepsis and can lead to organ failure. The current treatment for sepsis requires antibiotics, fluid drainage, blood transfusions, and dialysis. Since individual cases are caused by different microbes, the correct antibiotic must be chosen to treat the infection. This causes a delay in treatment, which leads to an increase in the mortality rate.
*IP Issue Date
None
*IP Type
Utility
*Stage of Development
Proof of Concept
*Web Links
Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipYoon YeoYeo LabPurdue Industrial and Physical Pharmacy
國家
United States
申請號碼
None
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備